The great thing about making predictions is that it is basically a win-win proposition: if you are correct in your predictions, you are celebrated for being a sage. If you are incorrect, you have the opportunity to learn from them and make better predictions for the next year. Wishing everyone a Happy New Year and a successful 2017!
LENSAR Inc. announced its filing of a Chapter 11 bankruptcy petition on Dec. 19 to reduce its debt, strengthen its balance sheet, and strengthen its platform for future growth, according to a press release from the company.
There was clinically significant less CME in patients who received trans-zonular triamcinolone acetonide, moxifloxacin hydrochloride, and vancomycin—known as the Dropless approach—in addition to an NSAID after cataract surgery.
Looking back over the past year and into the near future, Eric D. Donnenfeld, MD, Robert H. Osher, MD, and Mark Packer, MD, spoke to Ophthalmology Times about developments in diagnostic products and other tools used in cataract surgery. In addition, they discussed combination microinvasive glaucoma surgery (MIGS) and office-based surgery as new trends.
Cataract surgeons in the United States have long been envious of the IOL options available to their international colleagues. Finally, in 2016, American ophthalmologists gained access to some novel IOLs such as the Tecnis Symfony Extended Range of Vision IOL and the Tecnis Symfony Toric IOL (Abbott) that were approved by the FDA. According to leading cataract surgeons who spoke to Ophthalmology Times, these simultaneous approvals rank as the biggest cataract surgery news story of the year.